Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Anushka Bakshi

Say Goodbye to Costly Delays – Origins’ Clinical Trial Participant Simulations Have the Answer!

Lack of Patient Involvement in Clinical Trial Designs Causes Major Issues Low recruitment and retention of clinical trials is a key issue faced by many clinical trials. These can lead...

Origins – The Patient Focused Specialists

- PMLiVE

FDA approves Samsung Bioepis’ Stelara biosimilar Pyzchiva for inflammatory conditions

The drug has been authorised to treat plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis

- PMLiVE

AstraZeneca’s Imfinzi/Lynparza regimen recommended by CHMP to treat endometrial cancer

Almost 125,000 cases of endometrial cancer were diagnosed in Europe in 2022

- PMLiVE

Eli Lilly and Radionetics Oncology enter $140m radiopharma partnership

The strategic agreement also gives Lilly the exclusive right to acquire the biotech for $1bn

- PMLiVE

Roche announces CHMP recommendation for PiaSky in rare blood condition PNH

Paroxysmal nocturnal haemoglobinuria affects approximately 20,000 people worldwide

- PMLiVE

Almirall’s Ilumetri shown to improve and maintain well-being in plaque psoriasis patients

Nearly 77% of psoriasis patients report that the condition negatively affects their well-being

- PMLiVE

Find your brand’s edge, with dynamic competitive simulations

How the best teams in pharma stay at the top of their game

- PMLiVE

Johnson & Johnson’s Rybrevant granted EC approval for first-line NSCLC use

The drug was previously approved by the EU regulator for use after the failure of platinum-based therapy

- PMLiVE

Pfizer/BioNTech’s Omicron JN.1-adapted COVID-19 vaccine recommended by CHMP

The vaccine generated an improved response against several Omicron JN.1 sublineages

- PMLiVE

AbbVie announces CHMP recommendation for Tepkinly in follicular lymphoma

The blood cancer accounts for up to 30% of all non-Hodgkin lymphoma cases

- PMLiVE

Savara announces positive phase 3 results for molgramostim in rare lung disease

Autoimmune pulmonary alveolar proteinosis affects around one in every 150,000 people in the US

- PMLiVE

Taking a more mindful approach to meetings

Having a break between meetings can improve our well-being and the quality of our work

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links